• general@orthocell.com
  • +61 8 9360 2888
Orthocell EU/UK
  • Home
  • About
  • Team
  • Products
  • Invest
  • News
  • Practitioners
    • Striate+
    • Remplirâ„¢
    • OrthoACIâ„¢
    • Tendon
  • Contact
  • Region
    • Visit AU – Home
    • Visit Americas
    • Visit EU/UK
  • Home
  • About
  • Team
  • Products
  • Invest
  • News
  • Practitioners
    • Striate+
    • Remplirâ„¢
    • OrthoACIâ„¢
    • Tendon
  • Contact
  • Region
    • Visit AU – Home
    • Visit Americas
    • Visit EU/UK
29 May 2014
Orthocell Media Permalink

Orthocell to list on ASX

Orthocell 29 May 2014

Orthocell’s plans to list on the Australian Stock Exchange (ASX) have been featured in The Australian newspaper. 

Read more

30 Jun 2011
Orthocell Media Permalink

Stem cells show promise mending busted tendons

Orthocell 30 June 2011

Jill Margo, Health Editor at the Australian Financial Review, has published a feature article on Orthocell’s innovative autologous tenocyte implantation (ATI) therapy.

Read more

  • Recent posts

    • Quarterly Report – period ended 30 September 2025
    • Orthocell Announces Record Revenue of $3m for September Quarter
    • Orthocell Appoints First Distributor for Remplirâ„¢ in US$75m Canadian Market
    • Global opportunity emerges as Remplirâ„¢ is used in nerve-sparing prostate cancer surgery
    • Remplirâ„¢ Real World Evidence study delivers compelling 81% success rate
Next
  • © Orthocell Ltd. All rights reserved.

  • Contact Us

  • P: +61 8 9360 2888
    F: +61 8 9360 2899
    E: general@orthocell.com

  • News Updates

  • By entering your email address you are agreeing to our privacy policy.

BUILT WITH ♡ BY H^CK Orthocell EU/UK POWERED BY United Themes™
Please select the country you would like to view

Visit AU – Home

Visit Americas

Visit EU/UK

Join our mailing list

    By entering your email address you are agreeing to our privacy policy.


    Sign up to our EDM

    By entering your email address you are agreeing to our privacy policy.

    Patient expression of interest